Terumo : Announces Voting Results for the Election of Directors

Press Release Terumo Announces Voting Results for the Election of Directors

TOKYO, JAPAN - June 24, 2025 - Terumo Corporation (TSE: 4543) hereby announces the voting results for the election of directors held at the Annual General Meeting of Shareholders today. All candidates listed on May 14 announcement were elected as directors of Terumo Corporation. Also, Terumo appointed Representative Directors at the subsequent Board of Directors held today.

1. Directors (Excluding directors who serve as Audit and Supervisory Committee Members)

   Name	New position	Previous position
   Toshiaki Takagi	Representative Director and Chairman of the Board	Same as on the left
   Hikaru Samejima	Representative Director and Chief Executive Officer	Same as on the left
   Toshihiko Osada	Director and Group Senior Managing Executive Officer	Same as on the left
   Norimasa Kunimoto	Director and Group Managing Executive Officer	Same as on the left
   Hidenori Nishi	Independent Director	Same as on the left
   Keiya Ozawa	Independent Director	Same as on the left
   Mari Kogiso	Independent Director	Same as on the left

2. Directors who serve as Audit and Supervisory Committee Members

Name	New position	Previous position
Takanori Shibazaki	Director (Full-time Audit and Supervisory Committee Member)	Same as on the left
Soichiro Uno	Independent Director (Audit and Supervisory Committee Member)	Same as on the left
Keiko Hayashi	Independent Director (Audit and Supervisory Committee Member)	-

About Terumo

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to

provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been

supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell

therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at

large.